Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia

Oncogene

Volumn 26, Issue 16, 2007, Pages 2299-2307

  Carvalho, G ^a,b,c   Fabre, C ^a,b,c   Braun, T ^a,b,c   Grosjean, J ^a,b,c   Ades, L ^a,b,c,d   Agou, F ^e   Tasdemir, E ^a,b,c   Boehrer, S ^a,b,c   Israel, A ^e   Veron M ^e   Fenaux, P ^d   Kroemer, G ^a,b  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

Apoptosis; Mitochondria; NF B

Indexed keywords

CASPASE; CYTOCHROME C; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER PATIENT; CANCER RISK; CELL DEATH; CELL LOSS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE; MYELODYSPLASTIC SYNDROME; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN SECRETION;

ACUTE DISEASE; AMINO ACID SEQUENCE; APOPTOSIS; CELL LINE, TUMOR; HUMANS; I-KAPPA B KINASE; LEUKEMIA, MYELOID; MOLECULAR SEQUENCE DATA; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTEIN SUBUNITS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34147131297     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210043     Document Type: Article

References (30)

1. Agou F, Courtois G, Chiaravalli J, Baleux F, Coic YM, Traincard F et al. (2004a). Inhibition of NF-κB activation by peptides targeting NF-κB essential modulator (NEMO) oligomerization. J Biol Chem 279: 54248-54257.
2. Agou F, Traincard F, Vinolo E, Courtois G, Yamaoka S, Israel A et al. (2004b). The trimerization domain of NEMO is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains. J Biol Chem 279: 27861-27869.
3. Arkin MR, Wells JA. (2004). Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317.
4. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M et al. (2002). Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts. Leukemia 16: 2062-2071.
5. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F et al. (2006a). NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107: 1156-1165.
6. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. (2006b). Targeting NF-κB in hematologic malignancies. Cell Death Differ 13: 748-758.
7. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. (2002). Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 265: 39-47.
8. Castedo M, Hirsch T, Susin SA, Zamzami N, Marchetti P, Macho A et al. (1996). Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 157: 512-521.
9. Dev KK. (2004). Making protein interactions druggable: targeting PDZ domains. Nat Rev Drug Discov 3: 1047-1056.
10. Dombret H, Fenaux P, Soignet SL, Tallman MS. (2002). Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 39: 8-13.
11. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM et al. (2003). Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102: 987-995.
12. Fenaux P. (2005). Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS). Semin Oncol 32: S11-S15.
13. Ghosh S, Karin M. (2002). Missing pieces in the NF-κB puzzle. Cell 109(Suppl): S81-S96.
14. Gloire G, Dejardin E, Piette J. (2006). Extending the nuclear roles of IkappaB kinase subunits. Biochem Pharmacol (E-pub ahead of print 15 July 2006).
15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
16. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. (2001). NF-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2317.
17. Guzman ML, Swiderski CF, Howard DS, Grimes BA, RossiRM, Szilvassy SJ et al. (2002). Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99: 16220-16225.
18. Hassan Z, Fadeel B, Zhivotovsky B, Hellstrom-Lindberg E. (1999). Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39. Exp Hematol 27: 1322-1329.
19. Karin M, Yamamoto Y, Wang QM. (2004). The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26.
20. Lindberg EH. (2005). Strategies for biology- and molecular-based treatment of myelodysplastic syndromes. Curr Drug Targets 6: 713-725.
21. Luo JL, Kamata H, Karin M. (2005). IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 115: 2625-2632.
22. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y et al. (1997). Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM 14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11: 1469-1477.
23. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I et al. (1998). Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett 61: 157-164.
24. Nagai M, Seki S, Kitahara T, Abe T, Minato K, Watanabe S et al. (1984). A novel human myelomonocytoid cell line, P39/Tsugane, derived from overt leukemia following myelodysplastic syndrome. Gann 75: 1100-1107.
25. Nakamori Y, Emoto M, Fukuda N, Taguchi A, Okuya S, Tajiri M et al. (2006). Links Myosin motor Myo1c and its receptor NEMO/IKK-gamma promote TNF-alpha-induced serine307 phosphorylation of IRS-1. J Cell Biol 173: 665-671.
26. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
27. Smahi A, Courtois G, Rabia SH, Doffinger R, Bodemer C, Munnich A et al. (2002). The NF-κB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 11: 2371-2375.
28. Steensma DP, Bennett JM. (2006). The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81: 104-130.
29. Vardiman JW, Harris NL, Brunning RD. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
30. Zamzami N, Kroemer G. (2004). Methods to measure membrane potential and permeability transition in the mitochondria during apoptosis. Methods Mol Biol 282: 103-116.